Patents Examined by Jon M. Lockard
-
Patent number: 11975045Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.Type: GrantFiled: December 4, 2020Date of Patent: May 7, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: George Yancopoulos
-
Patent number: 11975080Abstract: This invention provides a DNA comprising any of the following (a) to (c): (a) a DNA comprising any of the base sequences of positions 16 to 831 of SEQ ID NO: 1, positions 16 to 822 of SEQ ID NO: 3, positions 16 to 825 of SEQ ID NO: 5, positions 16 to 819 of SEQ ID NO: 7, positions 16 to 834 of SEQ ID NO: 9, and positions 16 to 828 of SEQ ID NO: 11; (b) a DNA encoding a polypeptide comprising any of the amino acid sequences of positions 1 to 272 of SEQ ID NO: 2, positions 1 to 269 of SEQ ID NO: 4, positions 1 to 270 of SEQ ID NO: 6, positions 1 to 268 of SEQ ID NO: 8, positions 1 to 273 of SEQ ID NO: 10, and positions 1 to 271 of SEQ ID NO: 12; and (c) a complementary strand of the DNA (a) or (b).Type: GrantFiled: March 27, 2018Date of Patent: May 7, 2024Assignee: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITYInventors: Eiji Matsuura, Kazuko Kobayashi, Fumiaki Takenaka
-
Patent number: 11969458Abstract: The present invention provides a pharmaceutical preparation for treating a cardiovascular disease. Particularly, the present invention provides a formula of a neuregulin pharmaceutical preparation. The formula consist of neuregulin polypeptide, a buffer, a stabilizer, an excipient, a salt, and another component, can ensure the long-term stability of the neuregulin polypeptide, and can be used for treating a heart failure patient or a patient in a risk of the heart failure.Type: GrantFiled: June 5, 2020Date of Patent: April 30, 2024Assignee: Zensun (Shanghai) Science & Technology, Co., Ltd.Inventor: Mingdong Zhou
-
Patent number: 11970542Abstract: The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.Type: GrantFiled: November 8, 2018Date of Patent: April 30, 2024Assignees: Fred Hutchinson Cancer Center, Massachusetts Institute of TechnologyInventors: Damian J. Green, Yukang Lin, Oliver W. Press, Alice Tzeng, Karl Dane Wittrup
-
Patent number: 11958891Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.Type: GrantFiled: January 26, 2018Date of Patent: April 16, 2024Assignee: Surrozen Operating, Inc.Inventors: Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
-
Patent number: 11952420Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: GrantFiled: September 10, 2021Date of Patent: April 9, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Pashine, Michael L Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
-
Patent number: 11952417Abstract: The present invention is directed towards isolated antibodies that bind to IL12R?1. Specifically, anti-IL12R?1 antibodies, and methods of treatment using the antibodies are disclosed. The antibody is targeted against the beta 1 subunit of the receptors of IL-12 and IL-23 and is capable of blocking signaling by inflammatory cytokines IL-12 and IL-23, which could be useful in treating autoimmune inflammatory diseases, such as inflammatory bowel disease (IBD), RA, and psoriasis.Type: GrantFiled: December 9, 2021Date of Patent: April 9, 2024Assignee: Washington UniversityInventors: Marco Colonna, Cristiane Secca da Silva
-
Patent number: 11919954Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that specifically bind and inhibit TREM-1 signaling, wherein the antibodies do not bind to one or more Fc?Rs and do not induce the myeloid cells to produce inflammatory cytokines. Also provided are uses of such antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of autoimmune diseases.Type: GrantFiled: September 10, 2021Date of Patent: March 5, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Achal Pashine, Michael L. Gosselin, Aaron P. Yamniuk, Derek A. Holmes, Guodong Chen, Priyanka Apurva Madia, Richard Yu-Cheng Huang, Stephen Michael Carl
-
Patent number: 11912784Abstract: Provided herein are methods of treating eye disorders by administering an anti-VEGF antibody and/or conjugate to a subject having an eye disorder. The anti-VEGF antibody of the present disclosure may be an anti-VEGF antibody conjugate that includes a polymeric moiety that extends the half-life/effectiveness/properties of the antibody when administered to a subject. A method of the present disclosure includes administering one or more doses of an anti-VEGF antibody conjugate to a subject (e.g., human or other mammalian patient) in need of treating an eye disorder, where the anti-VEGF antibody conjugate may be administered less frequently than a standard anti-VEGF therapy to treat the eye disorder.Type: GrantFiled: October 9, 2020Date of Patent: February 27, 2024Assignee: Kodiak Sciences Inc.Inventors: Jason Ehrlich, Pablo Velazquez-Martin, Joel Naor, Daniel Victor Perlroth, Hong Liang
-
Patent number: 11905330Abstract: Autophagy is typically activated by starvation, allowing cells and organisms to mobilize their energy reserves. It is known that pharmacological modulation of autophagy represents a therapeutic potential. Here the inventors report that a protein that is released from cells in an unconventional, autophagy-dependent manner, namely, diazepam binding inhibitor (DBI), regulates autophagy. In particular, the inventors demonstrate that DBI inhibits autophagy and that the supply of recombinant DBI to mice enhanced glycolysis, enhanced lipogenesis, and inhibited fatty acid oxidation. The inventors show that neutralisation of DBI by a monoclonal antibody and an active immunization by means of an immunogenic DBI derivative eliciting autoantibodies induce autophagy and lead to metabolic changes that increase starvation-induced weight loss, reduce food intake upon refeeding, and reduce weight gain in response to hypercaloric diets.Type: GrantFiled: September 26, 2022Date of Patent: February 20, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS CITÉ, SORBONNE UNIVERSITÉInventors: Guido Kroemer, José Manuel Bravo San Pedro
-
Patent number: 11896618Abstract: The present invention relates, inter alia, to compositions and methods, including chimeric proteins comprising an extracellular domain of FMS like tyrosine kinase 3 ligand (FLT3L) and an extracellular domain of a Type II transmembrane protein that find use in the treatment of disease, such as cancer.Type: GrantFiled: August 13, 2020Date of Patent: February 13, 2024Assignee: Shattuck Labs, Inc.Inventors: Taylor Schreiber, George Fromm, Suresh De Silva
-
Patent number: 11878048Abstract: The invention relates to a protein for use in diagnosing and treating primary or secondary sclerosing diseases, a fusion protein, and nucleotide sequence and a vector, and to a pharmaceutical composition for use in diagnosing and treating primary or secondary sclerosing diseases.Type: GrantFiled: June 14, 2018Date of Patent: January 23, 2024Assignee: Kymab LimitedInventors: Martina Rauner, Lorenz C. Hofbauer, Uwe Platzbecker, Ulrike Baschant
-
Patent number: 11858989Abstract: The present disclosure relates to an antibody against Aquaporin-4 (AQP4). These peptide-specific AQP4 antibodies play a role to create a NMO model and contribute for investigating the NMO disease mechanisms and developing the strategy of the treatment.Type: GrantFiled: December 22, 2020Date of Patent: January 2, 2024Inventor: Chao-Lin Lee
-
Patent number: 11858992Abstract: The invention relates to antibodies that are capable of specifically binding TREM-1 and preventing the activation of TREM-1, a protein expressed on monocytes, macrophages and neutrophils. Such antibodies find utility in the treatment of individuals with an inflammatory disease, such as rheumatoid arthritis and inflammatory bowel disease.Type: GrantFiled: February 1, 2021Date of Patent: January 2, 2024Assignee: NOVO NORDISK A/SInventors: Vibeke Westphal Stennicke, Christine Brender Read, Susanne Nedergaard Grell, Charlotte Wiberg, Rune Salbo, Anette Henriksen, Soeren Padkjaer
-
Patent number: 11845806Abstract: Provided are proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.Type: GrantFiled: June 13, 2018Date of Patent: December 19, 2023Assignee: DINGFU BIOTARGET CO., LTD.Inventors: Ting Xu, Yan Luan, Jianjian Peng, Kai Fu, Meng Zhao, Xiaoxiao Wang
-
Patent number: 11827715Abstract: Provided herein are antibodies and methods of use thereof. The antibodies as disclosed herein bind to CD163+ on cells, such as on macrophages. These antibodies can be used in methods of treatment, such as methods of treating cancer.Type: GrantFiled: April 22, 2021Date of Patent: November 28, 2023Assignee: OncoResponse, Inc.Inventors: Kamal D. Puri, Siddarth Chandrasekaran, Melissa L. Conerly, Randi M. Simmons, Tyrel T. Smith, Mark E. Branum, Peter Probst
-
Patent number: 11819541Abstract: Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.Type: GrantFiled: June 14, 2021Date of Patent: November 21, 2023Assignee: Allergan, Inc.Inventors: Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin, David W. Dodick
-
Patent number: 11802151Abstract: The present disclosure provides an antibody that binds human Adhesion G Protein-Coupled Receptor B1 (BAI1) protein, compositions comprising the same, and use thereof in methods of detection, methods of diagnosis, and methods of treatment.Type: GrantFiled: November 3, 2020Date of Patent: October 31, 2023Assignee: Code Biotherapeutics, Inc.Inventors: Robert Getts, Jessica Bowers, Mindy Ellen George-Weinstein, Jacquelyn Gerhart
-
Patent number: 11787839Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.Type: GrantFiled: August 14, 2018Date of Patent: October 17, 2023Assignee: Board of Regents, The University of Texas SystemInventor: Hui-lin Pan
-
Patent number: 11780914Abstract: The present invention relates to monoclonal antibodies that specifically bind to human pituitary adenylate cyclase activating polypeptide (PACAP) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the monoclonal antibodies are also described.Type: GrantFiled: September 24, 2020Date of Patent: October 10, 2023Inventors: Agnes E. Hamburger, Cen Xu, Hong Sun, Yuan D. Shih, Dohan Weeraratne